Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial-Reference-Cited by-同舟云学术

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial

Published:2021 Issue:1 Volume:32 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Tate Shinichi¹^ORCID,Nishikimi Kyoko¹^ORCID,Matsuoka Ayumu¹^ORCID,Otsuka Satoyo¹^ORCID,Kato Kazuyoshi²^ORCID,Takahashi Yutaka³^ORCID,Shozu Makio¹^ORCID

Affiliation:

1. Department of Gynecology, Chiba University Hospital, Chiba, Japan.

2. Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.

3. Department of Clinical Oncology, International University of Health and Welfare (Ichikawa Hospital), Chiba, Japan.

Funder

Japanese Foundation for Multidisciplinary Treatment of Cancer

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2021.32.e8

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving treatment paradigms for platinum-resistant ovarian cancer: An update narrative review;Taiwanese Journal of Obstetrics and Gynecology;2024-07

2. Therapy‐related myeloid neoplasms after treatment for ovarian cancer: A retrospective single‐center case series;Journal of Obstetrics and Gynaecology Research;2024-04-17

3. Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies;Metabolites;2023-04-30

4. Investigation of the Possible Protective Effect of N-Acetylcysteine (NAC) against Irinotecan (CPT-11)-Induced Toxicity in Rats;Antioxidants;2022-11-10

5. Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer;Anticancer Research;2022-04-30